Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;28(1):105-22.
doi: 10.1016/j.hoc.2013.10.004.

Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Catherine Diefenbach  1 , Ranjana Advani
Affiliations
Review

Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Catherine Diefenbach et al. Hematol Oncol Clin North Am. 2014 Feb.

Abstract

Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unraveling the biology of HL have yielded a plethora of novel targeted therapies. This review provides an overview of the data behind the hype generated by these advances and addresses the question of whether or not clinically these targeted therapies offer hope for patients with HL.

Keywords: Brentuximab vedotin; Hodgkin lymphoma; Relapsed disease; Targeted therapies.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest

CD: Seattle Genetics, consulting and speakers bureau

RA: Seattle Genetics, research funding and advisory board, Genentech; advisory board and research funding, Millennium: The Takeda Oncology Company, research and advisory board.

Figures

Figure 1
Figure 1
Selected Novel Agents in the Context of the Biological Targets
See this image and copyright information in PMC

References

    1. Cancer facts and figures 2013. Atlanta, GA: American Cancer Society; 2013.

    1. http://seer.cancer.gov/statfacts/html/hodg.html

    1. Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol. 2013 Feb 10;31(5):592–598. - PMC - PubMed
    1. De Bruin ML, Sparidans J, van’t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009 Sep 10;27(26):4239–4246. - PubMed
    1. Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:323–329. - PubMed

Publication types

MeSH terms